Best strategies in recurrent or persistent Clostridium difficile infection

Area of Science:

• Infectious Diseases
• Gastroenterology
• Pharmacology

Background:

• Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated colitis and diarrhea.
• Increasingly virulent strains and a rise in elderly patients have led to more frequent and difficult-to-treat recurrent CDI.
• This review addresses the challenges and treatment strategies for recurrent CDI.

Purpose of the Study:

• To review current treatment strategies for recurrent Clostridium difficile infection (CDI).
• To discuss the efficacy and limitations of existing and emerging therapies for recurrent CDI.

Main Methods:

• A MEDLINE literature review was conducted.
• Search terms included "Clostridium difficile," "Clostridium difficile infection," and "recurrent Clostridium difficile infection."

Main Results:

• Metronidazole and vancomycin are mainstays for initial and first recurrent CDI.
• Vancomycin with a tapering regimen is recommended for second recurrences.
• Alternative treatments include fecal bacteriotherapy, rifaximin, nitazoxanide, probiotics, and intravenous immunoglobulin; fidaxomicin is recently approved.

Conclusions:

• Treating recurrent CDI remains a significant clinical challenge.
• Current recommendations are largely based on expert opinion due to limited high-quality studies.
• Emerging therapies like fidaxomicin and monoclonal antibodies offer potential future treatment avenues.